First global patient recruited for rare blood cancer study at King's

The King's College Hospital NHS Foundation Trust has announced the first global patient recruitment for the TAK-226-3001 Phase III trial. The study aims to enrol 300 participants, who may remain in the trial for up to five years. Recruitment was supported by the NIHR Clinical Research Facility at King’s. Credit: King’s College Hospital NHS Foundation Trust. The UK’s King’s College Hospital NHS Foundation Trust has announced the first global patient recruitment for TAK-226-3001, a Takeda Pharmaceuticals’ Phase III trial assessing elritercept against epoetin alfa for anaemia in adults with a rare type of blood cancer. The study involves patients with…

Source: Clinical Trials Arena